• Open label trial of add on lacosamide versus high dose monotherapy in patients with a seizure disorder
Many patients with epilepsy do not have complete seizure control from the first anti-seizure medication they take. Right now, it is not known whether it is better to increase the dose of the first medication, or to start a second medication at a low dose.

For this research study, we are looking for patients who had a seizure while taking only levetiracetam (Keppra). The subjects will continue to take levetiracetam, but will have lacosamide (Vimpat) added to their medication regime. Both of these medications will be taken at a low dose. We are trying to find out if taking two drugs at a low dose will provide better seizure control with fewer side effects than taking only one medication at a high dose. This study lasts about 6 months, and includes monthly study visits. Subjects will be asked to keep a daily seizure and side effect calendar. Both levetiracetam and lacosamide will be provided by the study, and subjects will be reimbursed up to $200 for participating.

Eligiblity criteria include:
1. Adults age 18 or older
2. Determined to have had at least two partial seizures by an Epilepsy Specialist, or to have had a single partial seizure with clinical and/or laboratory evidence of a high seizure recurrence risk
3. Monotherapy on levetiracetam (Keppra) less than or equal to 2000mg/day for at least two weeks
4. Breakthrough seizure while on stable dose (>1 week) of levetiracetam monotherapy regimen, not due to provocative factors (e.g. hypoglycemia, head trauma, missed medications)

For more information about this study, please contact Nichelle Llewellyn, the Epilepsy Research Coordinator, at (617) 732-5423, or email her at epilepsyresearch@partners.org.
Institution  –  BWH - Brigham and Women's Hospital, Boston, MA
Principal Investigator  – Jong Woo Lee, MD, PhD
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name  – Nichelle Llewellyn, CRC
Phone  – 617-732-5423